SCM
ZNTL icon

Sterling Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Sterling Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.89K Buy
+1,008
New +$4.02K ﹤0.01% 2631
2025
Q2 		– Sell
-1,027
Closed -$1.63K – 3413
2025
Q1 		$1.63K Sell
1,027
-914
-47% -$1.97K ﹤0.01% 2667
2024
Q4 		$5.88K Buy
1,941
+1,760
+972% +$5.77K ﹤0.01% 2386
2024
Q3 		$666 Buy
+181
New +$658 ﹤0.01% 2737

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Sterling Capital Management's ZNTL Position: Q2 2026 in Review

Sterling Capital Management opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q2 2026: 1,008 shares worth $4.89K. The stake represents ﹤0.01% of the portfolio and ranks #2631 among its holdings. This is a return to the name: Sterling Capital Management previously reported a position in ZNTL as recently as Q1 2025.

Sterling Capital Management first reported a position in ZNTL in Q3 2024 and has held it in 4 quarters since. The position peaked at $5.88K in Q4 2024. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Sterling Capital Management held 1,008 shares of Zentalis Pharmaceuticals worth $4.89K as of Q2 2026.
  • Zentalis Pharmaceuticals was a new Sterling Capital Management position in Q2 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2631 holding.
  • Sterling Capital Management first reported a position in Zentalis Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • Sterling Capital Management's Zentalis Pharmaceuticals position peaked at $5.88K in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.